Novexel begins Ph II NXL103 trial in CAP

French pharmaceutical company Novexel, a specialist in the development of novel antibiotics and anti-fungals, has advanced its steptogramin-class antibiotic, NXL103 (PI + PII), into Phase II assessment. The double-blind, randomized study is designed to investigate the efficacy, safety and tolerability of two doses of the drug used in the treatment of community-acquired pneumonia.

Under a pre-existing deal, France's drug major Sanofi-Aventis holds an option on the agent until the end of Phase IIa development. As a result of the new trial, Novexel is entitled to a quarterly option fee, financial details of which were not disclosed.